Radiolabelling of peptides for diagnosis and therapy of non-oncological diseases

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 4, 2003, Pages 223-237

  Sosabowski, J ^a   Melendez Alafort, L ^a   Mather, Stephen ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Peptides; Radionuclide imaging; Radiopharmaceuticals

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ASTATINE 211; BISMUTH 213; CARBOXYLIC ACID; CHOLECYSTOKININ; COPPER 64; CYCLAM DERIVATIVE; DEFEROXAMINE; GALLIUM; INDIUM 111; IODINE 125; IODINE 131; LACTOFERRIN; LUTETIUM; OCTREOTIDE[3 TYROSINE]; PENTETIC ACID; PEPTIDE; RADIOACTIVE IODINE; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SAMARIUM 153; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; TERBIUM; TRIFLUOROACETIC ACID; UNINDEXED DRUG; YTTRIUM 90;

BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CHEMICAL STRUCTURE; COLON CANCER; DIAGNOSTIC IMAGING; DRUG HALF LIFE; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; HUMAN; IMMUNOLOGY; INFECTION; INFLAMMATION; ISOTOPE LABELING; LUNG CANCER; ONCOLOGY; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; PROTEIN STRUCTURE; REVIEW; SOMATOSTATINOMA;

BINDING SITES; HALF-LIFE; HUMANS; INFECTION; INFLAMMATION; ISOTOPE LABELING; NEOPLASMS; PEPTIDES; RADIOPHARMACEUTICALS;

EID: 1842579039     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (115)

1. Fischman AJ, Babich JW, Strauss HW. A ticket to ride: peptide radiopharmaceuticals. J Nucl Med 1993;34:2253-63.
2. McAfee JG, Neumann RD. Radiolabeled peptides and other ligands for receptors overexpressed in tumor cells for imaging neoplasms. Nucl Med Biol 1996;23:673-6.
3. Blok D, Feitsma RIJ, Vermeij P, Pauwels EJK. Peptide radiopharmaceuticals in nuclear medicine. Eur J Nucl Med 1999;26:1511-9.
4. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
5. Reubi JC. Regulatory peptide receptors as molecular targets for cancer diagnosis and therapy. Q J Nucl Med 1997;41:63-70.
6. Lamberts SW, Koper JW, Reubi JC. Potential role of somatostatin analogues in the treatment of cancer. Eur J Clin Invest 1987; 17: 281-7.
7. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998;217:143-52.
8. Bakker WH, Krenning EP, Breeman WA, Koper JW, Kooij PP, Reubi JC et al. Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals. J Nucl Med 1990;31:1501-9.
9. de Jong M, Bakker WH, Breeman WAP, Bernard BF, Hofland LJ, Visser TJ et al. Pre-clinical comparison of [DTPA(0)] octreotide, [DTPA(0),Tyr(3)] octreotide and [DOTA(0),Tyr(3)] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int J Cancer 1998;75:406-11.
10. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
11. de Jong M, Breeman WAP, Bakker WH, Kooij PPM, Bernard BF, Hofland LJ et al. Comparison of In-111-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41.
12. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87:1073-7.
13. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid 2002;12:135-9.
14. Eschmann SM, Reischl G, Bilger K, Kupferschlager J, Thelen MH, Dohmen BM et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging 2002;29:760-7.
15. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med 2002;43:856-61.
16. Tiepolt C, Gruning T, Franke WG. Renaissance of 224 Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun 2002;23:61-6.
17. 166Ho labelled hydroxyapatite (HA) particles for radiosynovectomy. Nucl Med Biol 2002;29: 199-209.
18. Fischer M, Modder G. Radionuclide therapy of inflammatory joint diseases. Nucl Med Commun 2002;23:829-31.
19. Ures M, Savio E, Malanga A, Fernandez M, Paolino A, Gaudiano J. Physico-chemical characterisation and biological evaluation of 188-Rhenium colloids for radiosynovectomy. BMC Nucl Med 2002;2:1.
20. Valkema R, De Jong M, Bakker WH, Breeman VA, Kooij PP, Lugtenburg PJ et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPAloctreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-22.
21. Srivastava SC. Therapeutic radionuclides: making the right choice. In: Mather SJ, editor. Current directions in radiopharmaceutical research and development. Dordrecht: Kluwer Academic Publishers; 1996.p.63-79.
22. Rosch F, Herzog H, Stolz B, Brockmann J, Kohle M, Muhlensiepen H et al. Uptake kinetics of the somatostatin receptor ligand [Y-86]-DOTA-DPhe(1)-Tyr(3)-octreotide ([Y-86]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the Y-90-labelled analogue. Eur J Nucl Med 1999;26:358-66.
23. Lin KS, Baidoo KE, Zhan Y, Scheffel U, Wagner HNJ. Synthesis and evaluation of a high affinity rhenium bombesin analogue. In: Nicolini M, Mazzi U, editors. Technetium, rhenium and other metals in chemistry and nuclear medicine, vol. 5. Padova: Servizi Grafici Editoriali; 1999.p.533-8.
24. Zamora PO, Bender H, Gulhke S, Marek MJ, Knapp FF, Rhodes BA et al. Pre-clinical experience with Re-188-RC-160, a radiolabeled somatostatin analog for use in peptide-targeted radiotherapy. Anticancer Res 1997;17:1803-8.
25. Bakker WH, Krenning EP, Breeman WA, Kooij PPM, Reubi JC, Koper JW et al. In vivo use of a radioiodinated somatostatin analog - dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man. J Nucl Med 1991;32:1184-9.
26. Angelberger P, Virgolini I, Buchheit O, Egger M, Portner R, Kvaternik H. Radiopharmaceutical development of 123-I-Vasoactive Intestinal Peptide (VIP) for receptor scintigraphy in oncology. J Lab Comp Radiopharm 1995;37:502-3.
27. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 1995;36:1846-53.
28. Raderer M, Kurtaran A, Hejna M, Vorbeck F, Angelberger P, Scheithauer W et al. I-123-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer 1998;78:1-5.
29. Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-21.
30. Gourlet P, Rathe J, DeNeef P, Cnudde J, VandermeersPiret MC, Waelbroeck M et al. Interaction of lipophilic VIP derivatives with recombinant VIP1/PACAP and VIP2/PACAP receptors. Eur J Pharmacol 1998;354:105-11.
31. Blower PJ, Puncher MRB, Kettle AG, George S, Dorsch S, Leak A et al. Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism and dosimetry in humans. Eur J Nucl Med 1998;25:101-8.
32. 123I-K31440 as a potential SPECT ligand. Peptides 2002;23:453-60.
33. Bakker WH, Breeman WAP, vanderPluijm ME, deJong M, Visser TJ, Krenning EP. Iodine-131 labelled octreotide: not an option for somatostatin receptor therapy. Eur J Nucl Med 1996;23:775-81.
34. Wilbur DS. Radiohalogenation of proteins: an overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconj Chem 1992;3:433-70.
35. Garg S, Garg PK, Zalutsky MR. Acylation reagents for the radiohalogenation of peptides, J Lab Comp Radiopharm 1993;32: 212-3.
36. Garg PK, Alston KL, Welsh PC, Zalutsky MR. Enhanced binding and inertness to dehalogenation of alpha-melanotropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjug Chem 1996;7: 233-9.
37. 18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice. Nucl Med Biol 1994;21:819-25.
38. Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med 2001;28:929-38.
39. 125I-4-HO-Phenylacetyl-[Lys-Psi(CH2=NH -Arg=Phe11-t-Leu12-]NT(10-13): Radiosynthesis and characterisation. Nucl Med Commun 2000;21:568.
40. Iterbeke K, Chavatte K, Terriere D, Bergmann R, Johannsen B, Tourwe D et al. Optimisation of a neurotensin(8-31) analogue for radioiodination. Nucl Med Commun 2000;21:588.
41. Orlova A, Sjostrom A, Lebeda O, Lundqvist H, Tolmachev V. Intracellular retention of iodine-125 and astatine-211 labelled epidermal growth factor (EGF) in cultured A431 carcinoma cells. Nucl Med Commun 2000;21:577.
42. 18F-labelled neurotensin(8-13) analogues for positron emission tomography (PET): pharmacological and biochemical characterisation. Nucl Med Commun 2000;21:565.
43. 18F]-labelled linear peptides. Nucl Med Commun 2000;21:595.
44. Vaidyanathan G, Zalutsky MR. F-18 labeled chemotactic peptides: a potential approach for the pet imaging of bacterial-infection. Nucl Med Biol 1995;22:759-64.
45. Fredriksson A, Ekberg K, Ingvar M, Johansson BL, Wahren J, Stone-Elander S. In vivo biodistribution and pharmacokinetics of (18)F-labeled human C-peptide: evaluation in monkeys using positron emission tomography. Life Sci 2002;71:1361-70.
46. 18F-labelled linear peptides. Eur J Nucl Med Mol Imaging 2002;29: 754-9.
47. Bakker WH, Albert R, Bruns C, Breeman WAP, Hofland LJ, Marbach P et al. [In-111-DTPA-D-Phe1]-Octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-91.
48. Arano Y, Akizawa H, Uezono T, Akaji K, Ono M, Funakoshi S et al. Conventional and high-yield synthesis of DTPA-conjugated peptides: application of a monoreactive DTPA to DTPA-D-Phe(1)-octreotide synthesis. Bioconjng Chem 1997;8:442-6.
49. Reubi JC, Waser B, Schaer JC, Laederach U, Erion J, Srinivasan A et al. Unsulfated DTPA- and DOTA-CCK analogs as specific high-affinity ligands for CCK-B receptor-expressing human and rat tissues in vitro and in vivo. Eur J Nucl Med 1998;25:481-90.
50. Breeman WAP, Hofland LJ, Vanderpluijm M, Vankoetsveld PM, Dejong M, Setyonohan B et al. A new radiolabeled somatostatin analog [In-111-DTPA-D-Phe(1)]RC-160: preparation, biological-activity, receptor scintigraphy in rats and comparison with [In-111-DTPA-D-Phe(1)]Octreotide. Eur J Nucl Med 1994;21:328-35.
51. Breeman WAP, van Hagen PM, Kwekkeboom DJ, Visser TJ, Krenning EP. Somatostatin receptor scintigraphy using [In-111-DTPA(0)]RC-160 in humans: a comparison with [In-111-DTPA(0)] octreotide. Eur J Nucl Med 1998;25:182-6.
52. de Jong M, Bakker WH, Krenning EP, Breeman WAP, van der Pluijm ME, Bernard BF et al. Yttrium-90 and Indium-111 labelling, receptor binding and biodistribution of [DOTA(0),D-Phe(1), Tyr(3)]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
53. Virgolini I, Szilvasi I, Kurtaran M, Angelberger P, Raderer M, Havlik E et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39: 1928-36.
54. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136-48.
55. Breeman WAP, Hofland LJ, deJong M, Bernard BF, Srinivasan A, Kwekkeboom DJ et al. Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 1999;81:658-65.
56. Breeman WAP, de Jong M, Bernard BF, Kwekkeboom DJ, Srinivasan A, van der Pluijm ME et al. Pre-clinical evaluation of [In-111-DTPA-Pro(1), Tyr(4)] bombesin, a new radioligand for bombesin-receptor scintigraphy. Int J Cancer 1999;83:657-63.
57. van Hagen PM, Breeman WAP, Reubi JC, Postema PTE, van den Anker Lugtenburg PJ, Kwekkeboom DJ et al. Visualization of the thymus by substance P receptor scintigraphy in man. Eur J Nucl Med 1996;23:1508-13.
58. de Jong M, Bakker WH, Bernard BF, Valkema R, Kwekkeboom DJ, Reubi JC et al. Preclinical and initial clinical evaluation of In-111-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 1999;40:2081-7.
59. Behr TM, Jenner N, Behe M, Angerstein C, Gratz S, Raue F et al. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors. J Nucl Med 1999;40:1029-44.
60. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 2002;32:97-109.
61. de Jong M, Breeman WAP, Bernard HF, Kooij PPM, Slooter GD, van Eijck CHJ et al. Therapy of neuroendocrine tumors with radiolabeled somatostatin- analogues. Q J Nucl Med 1999;43:356-66.
62. 86Y-DTPA-octreotide. Nucl Med Biol 1997;24:275-86.
63. Smith-Jones PM, Stolz B, Albert R, Ruser G, Briner U, Macke HR et al. Synthesis and characterisation of [Y-90]-Bz-DTPA-oct: A yttrium-90- labelled octreotide analogue for radiotherapy of somatostatin receptor-positive tumours. Nucl Med Biol 1998;25:181-8.
64. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5.
65. Heppeler A, Froidevaux S, Macke HR, Jermann E, Behe M, Powell P et al. Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy. Chem Eur J 1999;5:1974-81.
66. Edreira M, Melendez-Alafort L, Mather SJ. Optimization of the small-scale synthesis of DOTA-Tyr3 -octreotide. Nucl Med Commun 2002;23:493-9.
67. Peterson JJ, Pak RH, Meares CF. Total solid-phase synthesis of 1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-functionalized peptides for radioimmunotherapy. Bioconjug Chem 1999;10:316-20.
68. Albert R, Smith-Jones P, Stolz B, Simeon C, Knecht H, Bruns C et al. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1,Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man. Bioorg Med Chem Lett 1998;8:1207-10.
69. Wagner SJ, Welch MJ. Gallium-68 labeling of albumin and albumin microspheres. J Nucl Med 1979;20:428-33.
70. Smith-Jones PM, Stolz B, Bruns C, Albert R, Reist HW, Fridrich R et al. Gallium-67/Gallium-68-[DFO]-Octreotide: a potential radiopharmaceutical for pet imaging of somatostatin receptor-positive tumors synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med 1994;35:317-25.
71. Froidevaux S, Eberle AN, Heppeler A, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000;7:971-94.
72. Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001;28:1751-7.
73. Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging 2002;29:821-30.
74. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996;23:957-80.
75. Anderson CJ, Pajeau TS, Edwards WB, Sherman ELC, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 1995;36:2315-25.
76. Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Anderson CJ. Structure-activity studies of Cu-64-labeled somatostatin analogs for diagnostic imaging and targeted radiotherapy. In: Nicolini M, Mazzi U, editors. Technetium, rhenium and other metals in chemistry and nuclear medicine, vol. 5. Padova: Servizi Grafici Editoriali; 1999.p.53-7.
77. Edwards WB, Anderson CJ, Fields GB, Welch MJ. Evaluation of collagen-based peptides as imaging agents for α3β1 integrin. In: Nicolini M, Mazzi U, editors. Technetium, rhenium and other metals in chemistry and nuclear medicine, vol. 5, Padova: Servizi Grafici Editoriali; 1999.p.527-31.
78. Edwards WB, Anderson CJ, Fields GB, Welch MJ. Evaluation of radiolabeled type IV collagen fragments as potential tumor imaging agents. Bioconjug Chem 2001;12:1057-65.
79. Liu S, Edwards DS. Tc-99m-labeled small peptides as diagnostic radiopharmaceuticals. Chem Rev 1999;99:2235-68.
80. Hom RK, Katzenellenbogen JA. Technetium-99m-labeled receptor-specific small-molecule radiopharmaceuticals: recent developments and encouraging results. Nucl Med Biol 1997;24: 485-98.
81. Okarvi SM. Recent developments in Tc-99(m)-labelled peptide-based radiopharmaceuticals: an overview. Nucl Med Commun. 1999;20:1093-112.
82. Dilworth JR, Parrott SJ. Radiopharmaceutically relevant chemistry of technetium and rhenium. In: Mather SJ, editor. Current directions in radiopharmaceutical research, vol. 30. Dordrecht: Kluwer Academic Publishers; 1996.p.1-28.
83. Babich JW, Solomon H, Pike MC, Kroon D, Graham W, Abrams MJ et al. Tc-99m-labeled hydrazino-nicotinamide derivatized chemotactic peptide analogs for imaging focal sites of bacterial-infection. J Nucl Med 1993;34:1964-74.
84. 99m-labeled human neutrophil peptide-1. J Nucl Med 1999;40: 2073-80.
85. 99mTc-UBI 29-41 for imaging of bacterial infections. Nucl Med Biol 2002;29: 413-22.
86. 99mTc-labeled antimicrobial peptides for detection of bacterial and Candida albicans infections. J Nucl Med 2001;42:788-94.
87. Nibbering PH, Welling MM, van den Broek PJ, van Wyngaarden KE, Pauwels EKJ, Calame W. Radiolabelled antimicrobial peptides for imaging of infections: a review. Nucl Med Commun 1998;19:1117-21.
88. Thakur ML, Eshbach J, Wilder S, John E, McDevitt MR. Tc-99m labeled sandostatin; preparation and preliminary evaluation. J Labelled Comp Radiopharm 1993;32:365-7.
89. Stalteri MA, Bansal S, Hider R, Mather SJ. Comparison of the stability of technetium-labeled peptides to challenge with cysteine. Bioconjng Chem 1999;10:130-6.
90. Trejtnar F, Laznicek M, Laznickova A, Mather SJ. Pharmacokinetics and renal handling of Tc-99m-labeled peptides. J Nucl Med 2000;41:177-82.
91. Giblin MF, Wang N, Hoffman TJ, Jurisson SS, Quinn TP. Design and characterization of alpha-melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Nat Acad Sci 1998;95:12814-8.
92. Lister-James J, Moyer BR, Dean RT. Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 1997;41:111-8.
93. Blum J, Handmaker H, ListerJames J, Rinne N. A multicenter trial with a somatostatin analog Tc-99m depreotide in the evaluation of solitary pulmonary nodules. Chest 2000;117:1232-8.
94. Blum J, Handmaker H, Rinne NA. Technetium labeled small peptide radiopharmaceuticals in the identification of lung cancer. Curr Pharm Des 2002;8:1827-36.
95. 99mTc-apcitide and correlation with contrast-enhanced venography in detection of acute deep vein thrombosis. J Nucl Med 1999;40: 2029-35.
96. Taillefer R. Radiolabeled peptides in the detection of deep venous thrombosis. Semin Nucl Med 2001;31:102-23.
97. 99mTc-apcitide scintigraphy with contrast venography for imaging acute DVT. J Nucl Med 2000;41:1214-23.
98. Knight LC. Radiolabeled peptide ligands for imaging thrombi and emboli. Nucl Med Biol 2001;28:515-26.
99. Lister-James J, Knight LC, Maurer AH, Bush LR, Moyer BR, Dean RT. Thrombus imaging with a technetium-99m-labeled activated platelet receptor-binding peptide. J Nucl Med 1996;37:775-81.
100. Moyer BR, Vallabhajosula S, Lister-James J, Bush LR, Cyr JE, Snow DA et al. Technetium-99m-white blood cell-specific imaging agent developed from platelet factor 4 to detect infection. J Nucl Med 1996;37:673-9.
101. Palestro CJ, Weiland FL, Seabold JE, Valdivia S, Tomas MB, Moyer BR et al. Localizing infection with a technetium-99m-labeted peptide: initial results. Nucl Med Commun 2001;22:695-701.
102. 99mTc-RP128 as a potential inflammation imaging agent: human dosimetry and first clinical results. J Nucl Med 2001;42:154-61.
103. Alberto R, Schibli R, Egli A, Schubiger AP, Abram U, Kaden TA. A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [Tc-99m(OH2)(3)(CO)(3)](+) from [(TcO4)-Tc-99m](-) in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 1998;120:7987-8.
104. 99mTc. J Nucl Med 2002;43:374-83.
105. Alberto R, Schibli R, Schubiger AP, Abram U, Pietzsch HJ, Johannsen B. First application of fac-[Tc-99m(OH2)(3)(CO)(3)](+) in bioorganometallic chemistry: design, structure, and in vitro affinity of a 5-HT1A receptor ligand labeled with Tc-99m. J Am Chem Soc 1999;121:6076-7.
106. 99mTc-labeled neuropeptide Y analogues as potential tumor imaging agents. Bioconjug Chem 2001;12:1028-34.
107. 99mTc labeling of highly potent small peptides. Bioconjug Chem 1997;8:621-36.
108. Verbeke K, Snauwaert K, Cleynhens B, Scheers W, Verbruggen A. Influence of the bifunctional chelate on the biological behavior of (99m)Tc-labeled chemotactic peptide conjugates. Nucl Med Biol 2000;27:769-79.
109. 99mTc labeled to a peptide by 4 methods. J Nucl Med 2001;42:1870-7.
110. 99mTc-neutrophil elastase inhibitor in monkeys. J Nucl Med 2000;41:363-74.
111. Babich JW, Fischman AJ. Effect of co-ligand on the biodistribution of Tc-99m-labeled hydrazino nicotinic-acid derivatized chemotactic peptides. Nucl Med Biol 1995;22:25-30.
112. Bangard M, Behe M, Guhlke S, Otte R, Bender H, Maecke HR et al. Detection of somatostatin receptor-positive tumours using the new Tc-99m-tricine-HYNIC-D-Phe(1)-Tyr(3)-octreotide: first results in patients and comparison with In-111-DTPA-D-Phe(1)- octreotide. Eur J Nucl Med 2000;27:628-37.
113. Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999;26:869-76.
114. 99mTc-Bitistatin, a platelet-binding polypeptide from viper venom. J Nucl Med 2000;41:1056-64.
115. Blankenberg FG, Tait JF, Blankenberg TA, Post AM, Strauss HW. Imaging macrophages and the apoptosis of granulocytes in a rodent model of subacute and chronic abscesses with radiolabeled monocyte chemotactic peptide-1 and annexin V. Eur J Nucl Med 2001;28:1384-93.